Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Transitional and progressive care can help patients achieve functional recovery faster in post-acute care

Transitional care has emerged as a way to reduce hospital readmissions, and progressive care nurses can play an integral role in efforts to help patients achieve functional recovery faster in post-acute care, according to an article in the June issue of Critical Care Nurse.

3 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

Using earlier surgical intervention more beneficial to patient with degenerative mitral valve disease

A more aggressive approach to treating degenerative mitral valve disease, using earlier surgical intervention and less invasive techniques, is more beneficial to the patient than "watchful waiting," according to an article in the June 2015 issue of The Annals of Thoracic Surgery.

2 Jun 2015

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone.

1 Jun 2015

$Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma$

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).

1 Jun 2015

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

The Lancet Diabetes & Endocrinology is pleased to announce that the following paper will be published to coincide with presentation at the 52nd ERA-EDTA Congress, taking place in London, UK, May 28 - 31, 2015.

1 Jun 2015

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.

30 May 2015

Heart failure patient spearheads Heather Cartwright Inherited Cardiomyopathy and Arrhythmia Project

Led by internationally-recognized cardiologists who are leaders in their field, the Peter Munk Cardiac Centre today announces the creation of an initiative to break ground in the cause, treatment and ongoing care of patients with an inherited, irregular heartbeat triggered by a rare cardiac structural condition.

30 May 2015

Patient characteristics may guide TKI use in CML

The likelihood of complications associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia may be reduced by considering patient factors and differences in the toxicity profiles of the different drug options, a review suggests.

29 May 2015

FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

The U.S. Food and Drug Administration (FDA) has approved Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog® (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes, Eli Lilly and Company announced today. Humalog U-200 KwikPen marks the first FDA approval of a concentrated mealtime insulin analog.

29 May 2015

Measuring kidney function and damage may help predict people at risk for heart disease

Simple measures of kidney function and damage may be just as good at predicting who is at risk for heart failure and death from heart attack and stroke as traditional tests of cholesterol levels and blood pressure, new Johns Hopkins Bloomberg School of Public Health-led research suggests.

29 May 2015

Sanford-Burnham, Takeda partner to develop new therapeutic targets for cardiovascular disease

Sanford-Burnham Medical Research Institute at Lake Nona today announced it has signed a two-year partnership agreement with Takeda Pharmaceutical Company Ltd. of Japan to study the potential role of several gene regulatory proteins as targets for the treatment of heart failure.

29 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced an upcoming poster presentation regarding its lead drug candidate, aldoxorubicin, at the 2015 American Society of Clinical Oncology Annual Meeting, which is being held May 29 - June 2, 2015 in Chicago.

27 May 2015

Mast Therapeutics initiates Phase 3 extension study of vepoloxamer in sickle cell disease

Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and arterial disease, today reported that it has initiated an open-label, multicenter Phase 3 extension study of vepoloxamer (MST-188) in sickle cell disease, referred to as "EPIC-E."

26 May 2015

CVRx announces presentation of positive data from Barostim Therapy for Heart Failure clinical trial at HRS 2015

CVRx, Inc., a private medical device company, announced that positive results from the 'Barostim Therapy for Heart Failure' randomized, controlled clinical trial were presented at the 2015 annual Scientific Sessions of the Heart Rhythm Society (HRS) in a Late-Breaking Clinical Trial Session. Results were presented by Dr. Michael Zile from the Medical University of South Carolina.

26 May 2015

Depression increases risk of mortality in patients with heart failure

Moderate to severe depression is associated with a 5-fold increased risk of all cause mortality in patients with heart failure, according to research presented today at Heart Failure 2015. The results from OPERA-HF show that risk was independent of comorbidities and severity of heart failure. Patients who were not depressed had an 80% lower mortality risk.

24 May 2015

Mayo Clinic hospitals earn top-tier High Performing distinction in U.S. News & World Report ratings

Mayo Clinic Hospitals in Rochester, Minn, and Phoenix earned the top-tier High Performing distinction in all five common care categories in the latest ratings by U.S. News & World Report.

21 May 2015

COPD associated with increased mortality in patients with atrial fibrillation, but not stroke

Chronic obstructive pulmonary disease, or COPD, is associated with increased risk of dying from a cardiovascular disease such as heart failure or a heart attack, as well as diseases not associated with the heart. However, COPD is not by itself associated with increased likelihood of having a stroke or a systemic embolism, according to a new research study.

21 May 2015

Heart Failure News and Research

Further Reading

Transitional and progressive care can help patients achieve functional recovery faster in post-acute care

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Using earlier surgical intervention more beneficial to patient with degenerative mitral valve disease

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Heart failure patient spearheads Heather Cartwright Inherited Cardiomyopathy and Arrhythmia Project

Patient characteristics may guide TKI use in CML

FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

Measuring kidney function and damage may help predict people at risk for heart disease

Sanford-Burnham, Takeda partner to develop new therapeutic targets for cardiovascular disease

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

Mast Therapeutics initiates Phase 3 extension study of vepoloxamer in sickle cell disease

CVRx announces presentation of positive data from Barostim Therapy for Heart Failure clinical trial at HRS 2015

Depression increases risk of mortality in patients with heart failure

Mayo Clinic hospitals earn top-tier High Performing distinction in U.S. News & World Report ratings

COPD associated with increased mortality in patients with atrial fibrillation, but not stroke

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News